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The blood-brain barrier (BBB) is composed of a
continuous endothelial layer with pericytes and
astrocytes in close proximity to offer homeostatic
control to the neurovasculature. The human de-
myelinating disease multiple sclerosis and the
animal counterpart experimental allergic enceph-
alomyelitis (EAE) are characterized by enhanced
permeability of the BBB facilitating oedema for-
mation and recruitment of systemically derived
in￿ ammatory-type cells into target tissues to
mediate eventual myelin loss and neuronal dys-
function. EAE is considered a useful model for
examining the pathology which culminates in
loss of BBB integrity and the disease is now
proving valuable in assessing compounds for
ef￿ cacy in limiting damage at neurovascular sites.
The precise mechanisms culminating in EAE-
induced BBB breakdown are unclear although
several potentially disruptive mediators have
been implicated and have been previously identi-
￿ ed as potent effectors of cerebrovascular da-
mage in non-disease related conditions of the
central nervous system. The review considers
evidence that common mechanisms may mediate
cerebrovascular permeability changes irrespect-
ive of the initial insult and discusses therapeutic
approaches for the control of BBB leakage in the
demyelinating diseases.
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Characteristic Features of the
Blood-Brain Barrier
The neurovasculature of the brain and spinal
cord originates from invading non-cerebral-
derived capillary cells which form a thin
continuous endothelial layer devoid of fene-
strations and pinocytic vesicles separating blood
from the central nervous system (CNS).1 In
close association with the endothelium are
pericytes which control endothelial cell pro-
liferation, regulate vessel contractility and
synthesize and secrete a variety of vasoactive
compounds.2 Typically, pericytes are poly-
morphic, elongated multibranched cells that
envelope endothelial cells in the micro-
vasculature. Pericyte contractility originates
from the presence of both smooth muscle
and non-smooth muscle isoforms of actin and
myosin. Interestingly, the degree of pericyte
contraction may either exacerbate or restrict
vessel leakage indicating the cell has a strong
in￿uence over blood-brain barrier (BBB) per-
meability.
On the abluminal surface of the microvessels
are situated the astrocytes with end feet in close
proximity to the endothelium offering physical
support and maintenance of cell function.3 One
particular morphological characteristic of the
BBB is the presence of tight junctions which
form the physical link between endothelial cells
and prevent the non-speci￿c passage of mole-
cules into CNS tissues.4 Tight junctions form a
complex branching network and together with
a relatively large density of pericytes, provide an
electrical resistance of about 2 3 103 Ohm/cm2
with low ionic and hydrophilic non-electrolyte
permeability.5,6 Other cellular membranes with
similar resistance values are located in the skin,
bladder and gastric epithelium. The selective
permeability of the endothelium may be a
consequence of the abundant mitochrondrial
population which provides a high metabolic
activity within the constituent cells.7 The en-
hanced metabolic state of the BBB is also
re￿ected in the amount of enzymic activity with
high concentrations of sodium-potassium ATP-
ase, c-glutamyl transpetidase, alkaline phospha-
tase and butyryl cholinesterase being observed
by histochemical analysis. 8- 10
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by the lipid solubility of compounds with hydro-
philic substances readily traversing the BBB.11
However, the apparent unrestricted entry of
some lipophilic substances can be controlled
by a family of intrinsic energy-dependent, mem-
brane-associated proteins which also prevent
the transport of highly toxic substances into
cerebral tissues.12 Essential non-lipid soluble
nutrients, such as glucose and certain amino
acids, must be transported across the neurovas-
culature through binding to speci￿c membrane-
bound proteins.13 The BBB can also metaboli-
cally control the entry of precursor substances,
which are derivatised and retained in cerebroen-
dothelial tissue.14
Clearly the normally restrictive BBB possesses
vital properties which closely regulate the
passage of essential and non-essential sub-
stances into and out of the CNS. Optimal
control of transport mechanisms is of primary
importance in maintaining neuronal function
and typical cerebral homeostasis. However, a
breakdown in normal barrier integrity can oc-
cur in many pathological conditions of the CNS
such as tumour development, hypertension and
ischaemia, to cause increased intercellular leak-
age at malfunctioning tight junctions and altera-
tions in transport mechanisms.15
The human demyelinating disease multiple
sclerosis (MS) is characterized by episodic mal-
function of the BBB which allows oedema
formation and in￿ammatory cell invasion of
CNS tissues.16 The inducible animal counterpart
experimental allergic encephalomyelitis (EAE)
also displays neurovascular disruption as a
prominent pathological feature.17 The purpose
of this article is to consider the mechanisms
and consequences of EAE-induced immune-
mediated insults on the BBB. In particular,
attention will focus on how resulting damage
can be measured and minimized through
pharmacological intervention.
Immunologically Induced Events
Mediating BBB Breakdown in
Experimental Models of MS
The traditional view of the CNS being an
immunoprivileged site originates from an ab-
sence of a true lymphatic system and the
presence of only minimal numbers of immuno-
competent cells, reduced antigen determinant
expression and low residual production of
immunological mediators.18 Improvements in
methods to monitor cell traf￿cking have pro-
vided evidence that brain and spinal tissues are
routinely surveyed by consistent numbers of
apparently non-speci￿cally activated T lympho-
cytes. Facilitated entry of immunocompetent T
cells into CNS tissue is closely regulated by the
BBB and, in particular, the luminal expression
of lymphocyte-directed intracellular adhesion
molecules.19,20
One CNS disease which is strongly in￿uenced
by events at neurovascular sites is the auto-
immune condition EAE, a highly reproducible
but genetically restricted model of human
demyelinating disease.21 The pathogenesis of
EAE is complex and offers many locations at
which the disease may be limited. The BBB can
be regarded as one such strategic site for
regulation and possible control of the disease.
However, and despite the importance of events
at the BBB in determining the occurrence of
EAE, only limited information is available con-
cerning mediators which disrupt the cerebral
endothelium and allow CNS access to in￿amma-
tory-type cells causing, in the more chronic
forms, demyelination and neuronal dysfunction.
Vasoactive amines have been regarded as
possible mediators of neurovascular disruption
in EAE.22 Histamine, released from predominant
numbers of systemic mast cells during EAE, is
present in excess during early neurological
disease and has been shown to increase pinocy-
tic vesicle activity in neurovascular isolates.23,24
Interestingly, use of the vasoactive amine ant-
agonist cyproheptidine can limit the neuro-
logical and histological expression of EAE but
the drug’s direct effects on the immunocompro-
mised BBB is not known.25 Differentially in-
creased prostaglandin levels have been re-
corded in CNS tissues from animals with the
acute and chronic-relapsing forms of EAE 26,27
and also in the cerebrospinal ￿uid from MS
patients.28 Prostaglandins of the E and F series
have profound regulatory effects on vascular
contractility and therefore could substantially
alter neurovascular function prior to and during
the expression of disease. However, treatment
with non-steroidal anti-in￿ammatory drugs, such
as indomethacin, does not prevent the develop-
ment of EAE and may intensify disease expres-
sion.29,30 The in￿ammatory cell-derived cyto-
kines interleukin-1 (IL-1) and tumour necrosis
factor-a (TNF-a) have been strongly implicated
in the induction of EAE and, in particular, as
mediators of BBB disruption. 31- 34 TNF-a levels
have also been found to correlate closely with
neurovascular disturbances in MS patients ex-
periencing active disease.35 Interestingly, in
vitro studies have also shown IL-1 and TNF-a to
possess permeability-inducing properties in
CNS-derived neuroendothelial preparations.31,32
Previous investigations by us have suggested a
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(NO) in mediating deleterious changes at the
BBB35 although pharmacological inhibition of
NO production, in an attempt to control EAE,
has provided con￿icting results.36- 39 Neverthe-
less, high levels of NO are present in EAE-
diseased CNS tissues providing the potential to
cause BBB damage. In associated preliminary
studies we have highlighted the importance of
the cellular and vasodisruptive polyamines in
EAE40,41 which complements earlier work illus-
trating the importance of the compounds in
non-immune-mediated CNS diseases.42,43 Both
NO and the polyamines can be generated
following activation of the N-methyl-D-aspartate
(NMDA) receptor located at neuronal and cere-
brovascular sites. 44- 46 Again, our studies have
shown that pharmacological antagonism of the
receptor can prevent BBB breakdown,47 reduce
polyamine levels48 and, as shown by others,49
the neurological symptoms of EAE.
The Pathology and Consequences
of BBB Breakdown in EAE
The neurovasculature of animals with EAE
shows increased numbers of pinocytic vesicles
apparently occurring as a result of alterations in
energy-dependent processes which regulate
transport mechanisms at the BBB.50,51 Metabolic
changes at the BBB are further indicated by a
marked reduction in the mitochondrial content
of the endothelium at the height of disease.51,52
Sodium-potassium ATPase activity is upregulated
which may have consequences on cellular
osmotic pressure and ￿uid uptake into CNS
tissues.53 Accumulation of oedematous ￿uid
within CNS tissues together with insoluble
deposits around nerves can lead to neuronal
dysfunction and neurological de￿cits in EAE.21,54
In addition to the development of CNS oedema
during EAE the parenchymal spaces become
characteristically in￿ltrated by cells of the
lymphocyte-macrophage series. In￿ammatory
products including degradative proteases and
soluble immune factors are released thus ensur-
ing continual recruitment and disruption of
target tissues.55,56
Techniques to Assess BBB
Integrity
Over 40 years have elapsed since the ￿rst
qualitative experiments on BBB permeability in
EAE were undertaken using trypan blue to
expose abnormal extravasation at sites of in-
￿ammatory cell in￿ltration.57 The subsequent
use of radiolabelled proteins and autoradio-
graphs of CNS tissues demonstrated vascular
disturbances occurred concurrently with initial
symptoms of disease.58,59 Immunohistochemical
techniques by Oldstone and Dixon,60 monitor-
ing leakage of serum ￿brinogen, b1C globulin
and IgG into CNS tissues, also revealed cerebral
vessel abnormalities prior to in￿ammatory cell
in￿ltration and neurological signs although sub-
sequent quantitative radioisotope methods
failed to distinguish between barrier leakage
and the occurrence of lesions.61 Reasons for the
discrepancies in the ￿ndings are unclear but
may be due to a variety of factors including
species differences, sample selection and rela-
tive sensitivities of techniques employed to
detect the pathological changes. Nevertheless,
an interval between the passage of solutes
across the BBB and the movement of in￿amma-
tory cells into the perivasculature would be
expected to occur.
Electron microscopic studies have revealed
structural alterations at neurovascular sites dur-
ing the development of EAE which led to the
suggestion of leakage through interendothelial
tight junctions as a mechanism to enhance BBB
permeability.62,63 Subsequent investigations
have failed to con￿rm the passage of substances
via interendothelial routes. Indeed, studies in
chronic-relapsing EAE, using magnetic reson-
ance imaging (MRI) scanning together with
histological evaluation, have found no evidence
of tight junction opening during obvious BBB
malfunction.64 MRI scanning, with the use of
gadolinium-linked contrast agents, has been
used with great effectiveness in EAE to demon-
strate physiological and metabolic changes in
the neurovasculature and show that energy-
dependent processes and active transport me-
chanisms are altered during BBB disruption. 65- 67
A particular advantage of the MRI technique
is the ability to evaluate ongoing EAE disturb-
ances in individual animals during the course
of acute and chronic-relapsing disease. Serial
scanning of lesions has revealed barrier disturb-
ances remain for more than a month although
shorter times of 1±2 weeks is typical. 68- 71 The
technique has also been used to con￿rm a
relationship between the severity of BBB dis-
turbances and the speci￿city and numbers of
immunocompetent T lymphocytes required to
induce EAE.72 Moreover, MRI has allowed a
detailed comparison between BBB changes in
EAE and during MS, at a structural level, which
has strengthened the relevance of the animal
model in the study of human demyelinating
diseases.
Ultrastructural studies of the BBB, prior to
MRI, were undertaken using the enzymic tracer
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BBB breakdown in EAEhorseradish peroxidase73,74 later to prove useful
in establishing the mechanisms involved in loss
of neurovascular integrity during acute and
chronic-relapsing EAE.75,76 In particular, the
marker was observed in transcytotic vesicles
and areas of in￿ammatory cell in￿ltration in
both forms of disease. Closer observation re-
vealed a large number of vesicles together with
tubular structures at parajunctional regions facil-
itating passage of the tracer across the endothe-
lial cells rather than through tight junctions.
Studies by Vorbrodt77 have used endogenous
plasma albumin in conjunction with immuno-
gold cytochemistry to observe the functional
state of the BBB at the ultrastructural level. The
technique allows various routes of transen-
dothelial or transvascular passage to be studied
with a quantitative evaluation of barrier dys-
function.
Use of the inert lipophobic compound manni-
tol to measure BBB disturbances has also been
described78 and used in EAE.79,80 Mannitol has
no carrier system and diffuses slowly across the
intact neurovasculature thus ensuring that any
increased passage of the molecule is due to
changes in BBB permeability. Neurovascular
leakage of radiolabelled mannitol precedes the
symptoms of EAE with both parameters corre-
lating well approximately 14 days post-inocula-
tion. Later studies by Lam17 showed that larger
molecular weight substances, such as insulin
and albumin, could not detect early changes in
barrier function during pre-neurological EAE
clearly illustrating the need for caution in the
selection of markers for determining BBB ab-
normalities.
Our studies have acknowledged the earlier
investigations of Leibowitz and Kennedy61 by
utilizing radiolabelled albumin in conjunction
with a second radioactive marker to quantitate
neurovascular breakdown.81 More recently we
have employed a radiolabelled marker, speci￿c
to in￿ammatory-type cells, to accurately quanti-
tate BBB disruption in EAE.82 In brief, the
procedure utilizes the binding of a synthetic
tuftsin antagonist to the receptor site expressed
on systemically-activated cells which eventually
breach the BBBand thereby provide an estimate
of leakage at neurovascular targets. Both tech-
niques detect similar alterations in cerebrovas-
cular permeability throughout the course of
EAE and the latter system also allows the
potential for c-camera imaging of disrupted
neuroendothelial sites. The development and
established use of highly reproducible and
re￿ned techniques to measure BBB disturbances
can guarantee a con￿dent evaluation of drug
effects on preventing or restoring normal neuro-
vascular function in a variety of CNS conditions.
However, of the numerous compounds admin-
istered in models of EAE only very few have
been assessed for direct effects on the BBB.
Pharmacological Control of
Abnormal BBB Permeability
Pathological conditions affecting the CNS often
feature BBB breakdown caused by the classic
components of acute and chronic in￿ammation
including histamine, arachidonate metabolites,
bradykinin and free radicals.83 Many of these
in￿ammatory mediators can normally be lim-
ited by anti-in￿ammatory-type drugs which
curiously often prove inactive at neurovascular
sites. However, one group of compounds to
unequivocally suppress enhanced permeability
at cerebrovascular sites are the glucocorticoids.
Original studies by Long and Holladay84 demon-
strated the homeostatic in￿uence of endogen-
ous corticosteroids on the BBB and suggested
permeability was closely governed by the
hypothalmic-pituitary-adrenal axis. Subsequent
investigations by Hedley-Whyte and Hsu85 and
Zlylan et al.86 in healthy rodents showed that
administration of the synthetic corticoid, dex-
amethasone (Dex), could reduce permeability
below normal levels for a variety of circulating
tracers. Interestingly, BBB permeability is en-
hanced following adrenalectomy and restored
to normal by Dex treatment clearly demonstrat-
ing a crucial role for the glucocorticoids in
maintaining integrity at the neurovasculature.
Several studies have detailed the importance
of the glucocorticoids in controlling EAE 87- 89
and more recent work by us has described
the corrective in￿uence of Dex on BBB break-
down when administered therapeutically.81
The broad effects produced following gluco-
corticoid administration does not allow a
precise evaluation of their actions at neuro-
vascular sites. However, in vivo and in vitro
studies have shown the compounds do have
the potential to act directly to limit dysfunction
on neuroendothelial cells and associated
targets.90,91
An alternative, receptor-based, approach to
the control of cerebrovascular damage in EAE
was ￿rst offered through the studies of Brosnan
et al.92 and Goldmuntz et al.93 who used the
a1-adrenergic antagonist prazosin to signi￿-
cantly improve BBB function and also reduce
the histological signs and symptoms of disease.
The possibility of receptor-mediated events
occurring in the loss of BBB integrity during
EAE has been more recently considered in our
studies using antagonists of the NMDA receptor
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locations. 47 The NMDA receptor antagonist MK-
801, which gates the open ion channel, drama-
tically curtails BBB leakage using prophylactic
and therapeutic dosing regimes. Additional pre-
liminary studies have revealed that increased
CNS polyamine levels during EAE can be sig-
ni￿cantly reduced following MK-801 treatment
strongly implicating a role for these agents in
the loss of cerebrovascular integrity.41,48 More-
over, antagonism of the polyamine site on the
NMDA receptor, through the use of the selec-
tive non-competitive neuroprotective antagonist
ifenprodil, has proved valuable in initial studies
to limit neuroendothelial breakdown.48 We en-
visage ongoing work with speci￿c antagonists
will assist in identifying the subtypes of NMDA
receptor and receptor sites involved in mediat-
ing BBB breakdown and may lead to the design
of new drugs to control cerebrovascular da-
mage.
Another compound with diverse effects is the
immunosuppressant cyclosporin A (CsA) which
has been used repeatedly to delay the onset and
progression of EAE and, in particular, BBB
breakdown in selected areas of the CNS.81,94,95
The drug can in￿uence abnormal cerebrovascu-
lar permeability during EAEby limiting the local
production of disruptive mediators. For exam-
ple, CsA has been found to reduce NO genera-
tion from vascular preparations and bind to
cytosolic proteins involved in the production of
neuroendothelial membrane disruptive poly-
amines. 96- 98 However, unlike the glucocorti-
coids and despite a high lipophilicity, CsA does
not readily accumulate in the CNS parenchyma
thus reducing pharmacological effects at CNS
targets. One reason for the low penetration of
cerebral tissues by CsA is the high af￿nity of the
drug for p-glycoprotein, a transmembrane e￿ux
transporter located on the luminal membrane of
neuroendothelial cells, which actively pumps
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FIG. 1. Major events mediating neuroimmune-directed BBB breakdown which may act as sites for drug intervention.
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BBB breakdown in EAElipophilic molecules back into the circula-
tion. 99- 101 Inactivation of the p-glycoprotein
pump, through the use of cytotoxic or non-
immunosuppressive compounds, has been
described102,103 raising the possibility that drug
delivery across the neurovasculature and into
the CNS could be enhanced by speci￿c pre-
treatment regimes.
Summary
The use of EAE as a prototype for the human
demyelinating condition MS has obvious limit-
ations but one prominent and characteristic
feature apparent in both diseases is a sustained
loss of BBB integrity. Although the precise
mechanisms of neurovascular breakdown in
EAE and MS are unknown, similar morphologi-
cal and immunological-associated changes do
occur. In non-disease related conditions of the
CNS a sequence of receptor-linked occurrences
appear to regulate activation of important bio-
chemical pathways which culminate in exten-
sive neurovascular damage with eventual
disruption of neuronal function. Improvements
in the design and use of detection systems to
monitor BBB breakdown together with analysis
of target tissues for possible mediators of
cerebrovascular leakage tentatively indicate si-
milar mechanisms may exist in the pathogenesis
of EAE and also MS (Fig. 1). Therefore, it is
intriguing to speculate that a common series of
events occur to cause abnormal BBB permeabil-
ity irrespective of the initial insult to the
neurovasculature. Pharmacological intervention
with site-speci￿c drugs may help to clarify the
pathways involved in neuroimmune-mediated
BBB breakdown and eventually offer therapies
to control an abberant and dominant aspect
central to the pathology of the demyelinating
diseases.
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